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by counterflow centrifugation. Eighteen patients died w ithin 3 months after bone marrow transplantation w ithout evidence of CMV infection, and they w ere e x cluded from analysis. T w enty-eight valuable seronega tive patients received m arrow from a seronegative, do nor, and 13 from a seropositive donor. All but 2 patients received acyclovir orally (4 x 4 0 0 mg/day) from days -9 to + 6 0 . CMV prophylaxis w ith im munoglobulin prepa rations w as not given. All blood products w ere prepared from random, CM V-unscreened blood-bank donors. The red cell concentrates w ere depleted of leukocytes by filtration, and leukocytes w ere rem oved from the plate let concentrates by centrifugation. None of the patients # DE WITTE ET AL 965 with seronegative donors showed any clinical sign com patible w ith CMV infection. Two nonfatal prim ary CMV infections occurred in the recipients of bone marrow from CM V-positive donors. One of the 59 patients de veloped interstitial pneum onia, in this case caused by
P n e u m o c y s tis c a r in ii.
Leukocyte depletion of blood products from random CM V-unselected blood donors appeared to prevent pri mary infection in C M V -seronegative BMT recipients. We conclude that prophylactic use of immunoglobulin preparations is not necessary to prevent CMV primoinfection in patients receiving leukocyte-depleted blood products and acyclovir prophylaxis during the first 2 months postgrafting.
Cytom egalovirus infection is the m ost com m on infectious cause of death after bone m arrow tra n sp la n ta tio n (7) . CM V infection after B M T has been reported to occur in 31-80% of the recipients (1) (2) (3) . CM V infection m ay arise from reactivation of a latent endogenous virus, from donor bone m arrow , blood products, or close physical contacts (4) . In CM V -seropositive recipients, reactivation of laten t endogenous virus is probably the m ost frequent source of infection, as m ay be concluded from the high incidence of CM V infection in recipients with positive CM V serology prior to B M T , as com pared to the relatively low incidence of CM V infection in C M V -seronegative recipients (5, 6) . T h e incidence of prim ary CM V infection in seronegative recipients ranged from 24% to 42% in five recent reports {1, [7] [8] [9] [10] .
Several approaches m ay reduce the incidence of CM V infec tion in seronegative recipients. Seronegative p atien ts receiving tran sp lan ts from seronegative donors were found to have the lowest risk of CM V infection (7) , b u t seronegative donors are not readily available. T h e use of blood products from seroneg ative blood donors has been successfully applied in B M T with m arrow from seronegative donors, w hereas no protection was observed am ong p atien ts receiving seropositive m arrow (8, 9) . Oral acyclovir given to prevent herpes infections may also provide protection against CM V infection {11, 12). Several studies have suggested th a t passive im m unization with CM V hyperim m une globulin m ay reduce the severity of CM V infec tion and the incidence of CM V interstitial pneum onia (IP)* after B M T (10, 13). In seronegative recipients, conflicting data have been reported. In one study prophylactic use of h y p erim mune globulin did not reduce the incidence of CM V infection (8) , but M eyers et al. reported com plete prevention in 11 seronegative recipients w ith seronegative-m arrow donors (10). Since the leukocyte fraction of donor blood has been im plicated as a source of virus (14, 15), a potential alternative is the use of leukocyte-poor blood products. W e presented here the 8-year experience in a bone m arrow tra n sp la n t program w ith a blood transfusion policy of leukocyte-poor blood products obtained from volunteer blood donors not selected for C M V -antibody status. after transplantation without evidence of CMV infection and were excluded from analysis. The remaining 41 patients with negative CMV serology formed the main group of this analysis. The median age of this group was 27 years (range: 13-44 years).
MATERIALS AND M ETHODS
The indications for BM T were: acute myeloid leukemia in 11 patients (10 in first complete remission [CR], 1 in partial remission); acute lymphocytic or undifferentiated leukemia or lymphoblastic lymphoma in 16 patients (12 in first CR, 4 in second CR); chronic myelogenous leukemia (CML) in 9 patients (6 in first chronic phase, 3 in accelerated phase); myelodysplastic syndromes in 4 patients; and severe aplastic anemia (SAA) in 1 patient.
C onditioning. The transport conditioning consisted of cyclophos phamide 60 mg/kg body weight (days -6 and -5 ), and total-body irradiation in two equal fractions of 450 cGy each on 2 consecutive days (days -2 and -1) using an 18-mV photon-beam linear accelerator (Saturne, CGR, BUC, France) at a dose rate of 5.5 cGy/min in 22 patients and 22 cGy/min in 16 patients. Lung and eye shielding was used on the second day of irradiation (16, 17) . Anthracyclines to reduce leukemic relapse after transplantation were added to the conditioning regimen in 22 patients (18) . The only patient with a mismatched family donor (1 mismatch at A-locus) received a total TBI dose of 12 Gy (two fractions of 6 Gy). One patient with SAA received total-lymphoid irradiation (six fractions with a total dose of 12 Gy). One patient who relapsed after BM T was retransplanted with unmanipulated marrow from the same donor, and the conditioning regimen consisted of busulphan (4 mg/kg body weight) orally for 4 days, followed by cyclophos phamide (50 mg/kg body weight) intravenously for 4 days.
D onor m arrow . Donor marrow was depleted of 97-98% of lympho cytes by counterflow-centrifugal élutriation as described before (19). Bone marrow was infused 24 hr after completion of the total-body irradiation.
M a n a g em en t o f th e p a tien ts. Details have been described in earlier reports (16, 17) . Twelve patients received immunoprophylaxis consist ing of CsA followed by weekly injections of methotrexate; 2 patients received methotrexate alone, and 27 patients CsA alone. All patients except the first 2 patients in this analysis received acyclovir orally (4x400 mg/day) from days -9 to -1-60 for prophylaxis of herpes virus infections. Acyclovir was given intravenously (3x5 mg/kg/day) when oral intake was impaired. CMV prophylaxis with hyperimmune globulin was not given. All patients were managed in single rooms with filtered air under positive pressure throughout the transplant period, and all received selective gut decontamination including co-trimoxazole for P n eu m o cystis carinii prophylaxis.
Blood products. All cell-containing blood products were irradiated (20 Gy) and prepared from random blood donors (nonpaid volunteers, about 50% of them have positive CMV serology). Leukocytes were removed from fresh red-cell concentrates (within 36 hr after collection) immediately prior to use by fiber filtration (NPBI CellSelect filter). This resulted in a white cell count of < 5 x l0 7/L in all instances, but most of the time the WCC was below the detection level of <1X107/L (20). Platelet concentrates were usually prepared from 6 buffy coats (one "random" platelet concentrate = 6 units) and subsequently sub jected to an additional centrifugation step for removal of the leukocytes (21). The number of nucleated cells per concentrate was less than 1X108 in 93% of the 286 tested concentrates. In case of refractoriness to platelets from random blood donors, platelet concentrates were prepared from CMV-unscreened HLA-matched blood-bank donors or relatives of the patient using cell separators. The single-donor-platelet concentrates contained less than 1X108 nucleated cells in 75% of the 60 tested concentrates. No granulocyte transfusions were given.
The general policy in our institution and in most referring hospitals was to give leukocyte-poor blood products to all BM T candidates and to all marrow recipients.
CMV m onitoring. IgG, IgA, and IgM antibodies to CMV were tested using enzyme-linked immunosorbent assays prior to BM T in serum of both donor and recipient (22, 23) . Reciprocal antibody levels of >10 arbitrary ELISA units (AEU) were considered positive (22, 23). A serum titer rise of 4 times or higher was considered significant. Serology was performed once weekly until 16 weeks after BM T and thereafter 3
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CMV-EA was determined in the urine of the recipient prior to BMT and weekly thereafter until 16 weeks postgrafting (24). When CMV-IP was suspected (vide infra) a bronchoalveolar lavage was always per formed, and the lavage material was cultured for the presence of CMV. D efinitions. CMV infection was defined either as primary infection or as reactivation: (1) primary infection was defined as a seroconverison
with antibody levels persistently above 10 AEU and/or positive cultures in a previously seronegative recipient; and (2) reactivation was defined as a rise in antibody level of at least fourfold and/or positive cultures in a previously seropositive patient.
CMV disease was defined as a clinical syndrome characterized by fever, leukocytopenia, hepatitis, interstitial pneumonia, or encephalitis associated with CMV-positive cultures obtained from the suspected sites.
CMV interstitial pneumonia was defined as a syndrome consisting of fever, tachypnea, hypoxia, chest X-ray compatible with IP, and demonstration of virus in bronchoalveolar lavage. S e ro p o sitiv e m a rro w re c ip ie n ts a n d C M V in fectio n . IgM a n tibodies, indicating recent or active CM V infection, were d eter m ined in 57 of the 61 CM V -seropositive recipients prior to B M T . Four of the 57 evaluated recipients had positive IgM antibodies. T h ree p atien ts had received transfusions in other institutions. T h e fourth patien t developed CM V interstitial pneum onia at presentation with C M L before any transfusion was given. T h is patient received a tra n sp la n t uneventfully 6 m onths after full recovery from the pneum onia th a t had re quired artificial ventilation for 2 weeks. N ine p atien ts died w ithin 3 m onths after B M T w ithout evidence of CM V infection. T h e rem aining 48 p atien ts were evaluated for CM V infection. Eleven p atien ts received m arrow from a seronegative donor. All developed CM V infection leading to fatal C M V -IP in 1 p atien t and fatal CM V aplasia in an o th er patient. T hirty-seven patients received m arrow from a seropositive donor or a donor with unknow n CM V serology. CM V infection was detected in 31 p atien ts leading to C M V -IP in 7 p atien ts (fatal in 4) and a nonfatal gastroenteritis in 1 p atien t ( Table 2 ). CM V was ex creted in the urine of 22 of 35 p atien ts w ith regular surveillance cultures of the urine. 
RESULTS
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